EquitySector - HealthcareVery High Risk
Regular
NAV (22-Aug-25)
Returns (Since Inception)
Fund Size
₹670 Cr
Expense Ratio
2.28%
ISIN
INF251K01UY7
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
27 Jun 2025
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
Since Inception
-0.65%
— (Cat Avg.)
Equity | ₹625.38 Cr | 93.28% |
Others | ₹45.04 Cr | 6.72% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Clearing Corporation Of India Ltd | Cash - Repurchase Agreement | ₹90.63 Cr | 13.52% |
Sun Pharmaceuticals Industries Ltd | Equity | ₹81.07 Cr | 12.09% |
Net Receivables / (Payables) | Cash - Collateral | ₹-45.59 Cr | 6.80% |
Divi's Laboratories Ltd | Equity | ₹39.57 Cr | 5.90% |
Apollo Hospitals Enterprise Ltd | Equity | ₹37.49 Cr | 5.59% |
Mankind Pharma Ltd | Equity | ₹36.93 Cr | 5.51% |
Cipla Ltd | Equity | ₹34.59 Cr | 5.16% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹32.02 Cr | 4.78% |
Fortis Healthcare Ltd | Equity | ₹27.01 Cr | 4.03% |
Gland Pharma Ltd | Equity | ₹24.11 Cr | 3.60% |
Abbott India Ltd | Equity | ₹24.08 Cr | 3.59% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹22.99 Cr | 3.43% |
Torrent Pharmaceuticals Ltd | Equity | ₹21.89 Cr | 3.27% |
Ajanta Pharma Ltd | Equity | ₹20.46 Cr | 3.05% |
Cohance Lifesciences Ltd | Equity | ₹19.97 Cr | 2.98% |
Biocon Ltd | Equity | ₹19.96 Cr | 2.98% |
Ipca Laboratories Ltd | Equity | ₹19.1 Cr | 2.85% |
AstraZeneca Pharma India Ltd | Equity | ₹18.37 Cr | 2.74% |
ICICI Prudential Life Insurance Co Ltd | Equity | ₹17.86 Cr | 2.66% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹17.69 Cr | 2.64% |
Aurobindo Pharma Ltd | Equity | ₹17.1 Cr | 2.55% |
Laurus Labs Ltd | Equity | ₹16.66 Cr | 2.48% |
Rainbow Childrens Medicare Ltd | Equity | ₹15.5 Cr | 2.31% |
Concord Biotech Ltd | Equity | ₹14.85 Cr | 2.21% |
Poly Medicure Ltd | Equity | ₹14.53 Cr | 2.17% |
Dr Reddy's Laboratories Ltd | Equity | ₹9.53 Cr | 1.42% |
Dr. Lal PathLabs Ltd | Equity | ₹8.38 Cr | 1.25% |
Natco Pharma Ltd | Equity | ₹7.15 Cr | 1.07% |
Lupin Ltd | Equity | ₹3.86 Cr | 0.58% |
Sanofi India Ltd | Equity | ₹2.68 Cr | 0.40% |
Large Cap Stocks
44.29%
Mid Cap Stocks
24.20%
Small Cap Stocks
24.79%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹607.52 Cr | 90.62% |
Financial Services | ₹17.86 Cr | 2.66% |
Standard Deviation
This fund
--
Cat. avg.
15.60%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
1.09
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.99
Higher the better
Since June 2025
ISIN INF251K01UY7 | Expense Ratio 2.28% | Exit Load 1.00% | Fund Size ₹670 Cr | Age 1 month | Lumpsum Minimum ₹1,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Total AUM
₹44,086 Cr
Address
Crescenzo, 7th Floor, G-Block, Mumbai, 400 051
Your principal amount will be at Very High Risk
EquitySector - HealthcareVery High Risk
Regular
NAV (22-Aug-25)
Returns (Since Inception)
Fund Size
₹670 Cr
Expense Ratio
2.28%
ISIN
INF251K01UY7
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
27 Jun 2025
Your principal amount will be at Very High Risk
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
Since Inception
-0.65%
— (Cat Avg.)
Equity | ₹625.38 Cr | 93.28% |
Others | ₹45.04 Cr | 6.72% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Clearing Corporation Of India Ltd | Cash - Repurchase Agreement | ₹90.63 Cr | 13.52% |
Sun Pharmaceuticals Industries Ltd | Equity | ₹81.07 Cr | 12.09% |
Net Receivables / (Payables) | Cash - Collateral | ₹-45.59 Cr | 6.80% |
Divi's Laboratories Ltd | Equity | ₹39.57 Cr | 5.90% |
Apollo Hospitals Enterprise Ltd | Equity | ₹37.49 Cr | 5.59% |
Mankind Pharma Ltd | Equity | ₹36.93 Cr | 5.51% |
Cipla Ltd | Equity | ₹34.59 Cr | 5.16% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹32.02 Cr | 4.78% |
Fortis Healthcare Ltd | Equity | ₹27.01 Cr | 4.03% |
Gland Pharma Ltd | Equity | ₹24.11 Cr | 3.60% |
Abbott India Ltd | Equity | ₹24.08 Cr | 3.59% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹22.99 Cr | 3.43% |
Torrent Pharmaceuticals Ltd | Equity | ₹21.89 Cr | 3.27% |
Ajanta Pharma Ltd | Equity | ₹20.46 Cr | 3.05% |
Cohance Lifesciences Ltd | Equity | ₹19.97 Cr | 2.98% |
Biocon Ltd | Equity | ₹19.96 Cr | 2.98% |
Ipca Laboratories Ltd | Equity | ₹19.1 Cr | 2.85% |
AstraZeneca Pharma India Ltd | Equity | ₹18.37 Cr | 2.74% |
ICICI Prudential Life Insurance Co Ltd | Equity | ₹17.86 Cr | 2.66% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹17.69 Cr | 2.64% |
Aurobindo Pharma Ltd | Equity | ₹17.1 Cr | 2.55% |
Laurus Labs Ltd | Equity | ₹16.66 Cr | 2.48% |
Rainbow Childrens Medicare Ltd | Equity | ₹15.5 Cr | 2.31% |
Concord Biotech Ltd | Equity | ₹14.85 Cr | 2.21% |
Poly Medicure Ltd | Equity | ₹14.53 Cr | 2.17% |
Dr Reddy's Laboratories Ltd | Equity | ₹9.53 Cr | 1.42% |
Dr. Lal PathLabs Ltd | Equity | ₹8.38 Cr | 1.25% |
Natco Pharma Ltd | Equity | ₹7.15 Cr | 1.07% |
Lupin Ltd | Equity | ₹3.86 Cr | 0.58% |
Sanofi India Ltd | Equity | ₹2.68 Cr | 0.40% |
Large Cap Stocks
44.29%
Mid Cap Stocks
24.20%
Small Cap Stocks
24.79%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹607.52 Cr | 90.62% |
Financial Services | ₹17.86 Cr | 2.66% |
Standard Deviation
This fund
--
Cat. avg.
15.60%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
1.09
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.99
Higher the better
Since June 2025
ISIN INF251K01UY7 | Expense Ratio 2.28% | Exit Load 1.00% | Fund Size ₹670 Cr | Age 1 month | Lumpsum Minimum ₹1,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Total AUM
₹44,086 Cr
Address
Crescenzo, 7th Floor, G-Block, Mumbai, 400 051
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments